Scholarlink

Purpose <p>TACE is the standard treatment for intermediate-stage unresectable hepatocellular carcinoma. However, the optimal concentration of doxorubicin in cTACE remains uncertain. This study evaluates the efficacy and safety of high-concentration doxorubicin (25&#xa0;mg/mL) compared to a lower concentration (2&#xa0;mg/mL) in patients undergoing cTACE.</p> Methods <p>A retrospective cohort study was conducted on HCC patients who underwent conventional TACE with either 2&#xa0;mg/mL or 25&#xa0;mg/mL doxorubicin. The primary outcome was overall survival, and secondary outcomes included disease response, disease-free survival, and adverse events. Kaplan–Meier analysis and Cox proportional hazards regression were used to assess survival outcomes, adjusting for baseline characteristics such as Barcelona Clinic Liver Cancer stage, Child–Pugh score, and ECOG performance status.</p> Results <p>No statistically significant difference in overall survival was observed between the two groups (<i>p</i> = 0.757), with median survival of 788&#xa0;days (25.6&#xa0;months) in the low-concentration group and 710&#xa0;days (23.3&#xa0;months) in the high-concentration group. Cox regression analysis revealed significantly increased mortality risk in advanced BCLC stages (Stage B: HR 5.51, <i>p</i> = 0.004; Stage C: HR 8.83, <i>p</i> = 0.003) compared to Stage A. Disease response and DFS at 1, 2, and 3-year intervals showed no significant differences. Adverse event rates were comparable, with no significant increase in post-embolization syndrome in the high-concentration group (<i>p</i> = 0.617).</p> Conclusion <p>No significant difference in survival, treatment response, or adverse events was demonstrated between groups. Baseline differences suggest a shift towards offering treatment to patients with more advanced disease in the later cohort.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

High-concentration doxorubicin in cTACE: a retrospective cohort study of efficacy and safety

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月31日

查看全文
  • Siobhan Lee,
  • Elliot Lee,
  • Christian Abel

摘要

Purpose

TACE is the standard treatment for intermediate-stage unresectable hepatocellular carcinoma. However, the optimal concentration of doxorubicin in cTACE remains uncertain. This study evaluates the efficacy and safety of high-concentration doxorubicin (25 mg/mL) compared to a lower concentration (2 mg/mL) in patients undergoing cTACE.

Methods

A retrospective cohort study was conducted on HCC patients who underwent conventional TACE with either 2 mg/mL or 25 mg/mL doxorubicin. The primary outcome was overall survival, and secondary outcomes included disease response, disease-free survival, and adverse events. Kaplan–Meier analysis and Cox proportional hazards regression were used to assess survival outcomes, adjusting for baseline characteristics such as Barcelona Clinic Liver Cancer stage, Child–Pugh score, and ECOG performance status.

Results

No statistically significant difference in overall survival was observed between the two groups (p = 0.757), with median survival of 788 days (25.6 months) in the low-concentration group and 710 days (23.3 months) in the high-concentration group. Cox regression analysis revealed significantly increased mortality risk in advanced BCLC stages (Stage B: HR 5.51, p = 0.004; Stage C: HR 8.83, p = 0.003) compared to Stage A. Disease response and DFS at 1, 2, and 3-year intervals showed no significant differences. Adverse event rates were comparable, with no significant increase in post-embolization syndrome in the high-concentration group (p = 0.617).

Conclusion

No significant difference in survival, treatment response, or adverse events was demonstrated between groups. Baseline differences suggest a shift towards offering treatment to patients with more advanced disease in the later cohort.